These observations would suggest, it is plausible that glutamate-Ca2+ NVC pathways in patients with ME/CFS may be impaired because of reduced TRPM3 activity and Ca2+ mobilisation. This evidence concerns the gene TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome.